Meningioma
Conditions
Interventions
Training set:Sox11,PITX1 immunohistochemical staining
validation set:Sox11,PITX1 immunohistochemical staining
Sponsors
Southwest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: From January 2014 to December 2024, the pathological diagnoses of "meningiomas" at the First Affiliated Hospital and the Second Affiliated Hospital of the Army Medical University were re-evaluated by 2 pathologists specializing in central nervous system tumors according to the 5th edition (2021) of the WHO Classification of Central Nervous System Tumors for all pathological diagnoses and grading of meningiomas. 1. Essential criteria: Classic histopathological features matching at least one of the meningiomasubtypes OR Suggestive histopathological features combined with biallelic inactivation of NF2 or other classic drivers of conventional meningioma (TRAF7, AKT1, KLF4, SMO,PIK3CA), clear cell meningioma (SMARCE1), or rhabdoid meningloma (BAP1) OR Suggestive histopathological features combined with one of the defined DNA methylation classes of meningioma 2. Desirable criteria: Meningeal localization;EMA immunoreactivity;Strong and difuse SSTR2A immunoreactivity; Classic copy-number alterafions of NF2-mutant meningioma, such as monosomy22/22q in lower-grade meningiomas, with additional losses of 1p, 6, 10g, 14g, and/or 18 in higher-grade meningiomas. 3. Grading criteria: (1) CNS WHo grade 2 4 to 19 mitotic figures in 10 consecutive HPF of each 0.16 mm? (at least 2.5/mm2 ) OR Unequivocal brain invasion (not only perivascular spread or indentation of brainwithout pial breach) OR Specific morphological subtype (chordoid or clear cell) OR At least three of the following: Increased cellularity; Small cells with high N:C ratio; Prominent nucleoli; Sheeting (uninterrupted patternless or sheet-like growth); Foci of spontaneous (nan-iatrogenic) necrosis CNS WHO grade 3 20 or more mitotic figures in 10 consecutive HPF of each 0.16 mm2 (at least 12.5/mm2) OR Frank anaplasia (sarcoma-, carcinoma-, or melanoma-like appearance) OR TERT promoter mutation OR Homozygous deletion of CDKN2A and/or CDKN2B
Exclusion criteria
Exclusion criteria: 1. According to the 5th edition (2021) of the WHO Classification of Central Nervous System Tumors, cases with unclear diagnosis reviewed by 2 pathologists specializing in central nervous system subcategories; 2. Cases with incomplete or missing data: including cases lacking qualified tissue samples and sections, and cases with missing follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunohistochemical score;Progression-free survival; | — |
Countries
China
Contacts
Public ContactCong Chen
Southwest Hospital
Outcome results
None listed